All In Biotech

Drug Trial Radar · NCT07211685

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 19, 2025

Primary completion

Nov 29, 2027

Study completion Nov 29, 2027

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a high risk of developing chronic kidney disease (CKD), a condition in which there is progressive loss in kidney function over time. The kidneys soon lose their ability to remove waste products from the body properly, resulting in end-stage kidney disease. A common sign of decreasing kidney function is the presence of excess protein in the urine that is not usually found with healthy kidneys. This condition is known as proteinuria. The study drug, BAY 3401016 (a monoclonal antibody), is a type of medicine that blocks a protein called Semaphorin 3A (Sema3A), which is thought to be involved in causing kidney damage in AS. By blocking the action of the Sema3A protein, BAY 3401016 may prevent proteinuria and slow down the loss in kidney function due to AS. The main purpose of this study is to learn more about how well BAY 3401016 works in slowing down the loss in kidney function in adults with a rapidly progressing AS.

Conditions

  • Alport Syndrome

Interventions

  • BAY 3401016Drug

    BAY 3401016

  • PlaceboOther

    Placebo to BAY 3401016

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinary albumin creatinine ratio (UACR) ratio to baseline averaged over 16, 20 and 24 weeks of treatmentTime frame: From the start of study intervention, over 16, 20 and 24 weeks of treatment, until the last follow-up visit, 90 days ± 3 days after EoT

Locations

51 sites in 15 countries. Site status is shown where the registry gives one.

  • Nephrology Clinic at The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama

  • The Peggy and Harold Katz Family Drug Discovery Center - Nephrology

    Miami, Florida

  • Cardio Renal Institute

    Chubbuck, Idaho

  • Tufts Medical Center | Nephrology Department

    Boston, Massachusetts

  • Renal Disease Research Institute | Landry

    Dallas, Texas

  • Hospital Británico

    Buenos Aires, Argentina

  • Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)

    Buenos Aires, Argentina

  • Centro de Rehabilitacion Cardiovascular | San Luis, Argentina

    San Luis, Argentina

  • Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares S.A.

    Santa Fe, Santa Fe Province, Argentina

  • Centre hospitalier universitaire de Québec (CHUQ) | Nephrology

    Québec, Canada

  • St Joseph's Healthcare Hamilton | Cardiology

    Hamilton, Ontario, Canada

  • Montreal General Hospital | Nephrology

    Montreal, Quebec, Canada

  • Peking University First Hospital - Department of Pediatrics

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital, Sun Yat-sen University - Department of Pediatrics

    Guangzhou, Guangdong, China

  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology - Pediatric Nephrology and Immunology

    Wuhan, Hubei, China

  • Children's Hospital, Zhejiang University School of Medicine - Department of Nephrology

    Hangzhou, Zhejiang, China

  • Fakultní nemocnice Hradec Kralové - Nefrologická klinika

    Hradec Králové, Hradec Králové Region, Czechia

  • CHU de Brest - Hopital La Cavale Blanche - Service de Nephorologie-Hémodialyse-Transplantation

    Brest, Brittany Region, France

  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Necker-Enfants Malades - Service d'Hopital De Jour Néphrologie adulte

    Paris, Île-de-France Region, France

  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital de Rangueil - Nephrologie et transplantation d'organes

    Toulouse, Occitanie, France

  • Charité Mitte - Nephrologie und Internistische Intensivmedizin

    Berlin, Germany

  • Universitaetsklinikum Erlangen - Medizinische Klinik 4, Nephrologie, Hypertensiologie

    Erlangen, Bavaria, Germany

  • Universitaetsmedizin Goettingen (UMG) - Klinik fuer Nephrologie und Rheumatologie

    Göttingen, Lower Saxony, Germany

  • Universitaetsklinikum Koeln - Klinik II fuer Innere Medizin - Nephrologie, Rheumatologie, Diabetologie, Innere Medizin

    Cologne, North Rhine-Westphalia, Germany

  • Mavani Research Center

    Ahmedabad, Gujarat, India

  • All India Institute of Medical Sciences (AIIMS) - New Delhi

    New Delhi, National Capital Territory of Delhi, India

  • K.G. Hospital

    Coimbatore, Tamil Nadu, India

  • The Institute of Post Graduate Medical Education & Research (IPGMER) (SSKM Hospital)

    Kolkata, West Bengal, India

  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto

    Bologna, Emilia-Romagna, Italy

  • Ospedale Pediatrico Bambino Gesù - Nefrologia

    Rome, Lazio, Italy

  • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene

    Genoa, Liguria, Italy

  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia

    Brescia, Lombardy, Italy

  • Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital

    Osaka, Japan

  • Japanese RedCross Aichi Medical Center Nagoya Daini Hospital

    Nagoya, Aichi-ken, Japan

  • Saitama Prefectural Children's Medical Center

    Chuo-Ku, Tokyo, Japan

  • Uniwersytecki Szpital Kliniczny w Poznaniu - Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych

    Poznan, Greater Poland Voivodeship, Poland

  • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy - Centrum Wsparcia Badań Klinicznych

    Warsaw, Masovian Voivodeship, Poland

  • Hospital de Curry Cabral - Nephrology Department

    Lisbon, Portugal

  • Unidade Local de Saúde de São João E.P.E. - Hospital São João - Serviço de Nefrologia

    Porto, Portugal

  • Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department

    Vila Nova de Gaia, Porto District, Portugal

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.